What Are Occluders?
Occluders, as implants for interventional therapy, are used to treat congenital heart disease: atrial septal defect, ventricular septal defect, and open arterial ducts, which have been widely used in clinical practice.
- Occluders, as implants for interventional therapy, are used to treat congenital heart disease: atrial septal defect, ventricular septal defect, and open arterial ducts, which have been widely used in clinical practice.
Simple introduction to occluder
- Congenital heart disease is a cruel "killer" that endangers the health and life of children. According to statistics, about 6 out of every 1,000 newborns suffer from congenital heart disease. According to the birth rate of the population and the incidence of congenital heart disease, it is estimated that 150,000 sick children are born every year in China. In the onset of congenital heart disease, ventricular septal defects ("holes" appear between left and right ventricles), atrial septal defects ("holes" between left and right ventricles), and arterial ducts are not closed (there is a channel between the aorta and the pulmonary artery). The most common clinical congenital malformations. Occluders, as implants for interventional therapy, are used to treat congenital heart disease: atrial septal defect, ventricular septal defect, and open ductus arteriosus, which have been widely used in clinical practice. The main principle is to block the "leakage" between the left and right ventricles, the "leakage" between the left and right ventricles, and the passage between the aorta and the pulmonary artery. Congenital heart disease occluders are divided into arterial duct occluders, atrial septal defect occluders and ventricular septal defect occluders.
The atrial septal defect occluder and the atrial septal defect occluder are self-expanding double disc structures densely woven from a nickel-titanium alloy mesh. The structure and principle are similar to those of an arterial duct occluder.
Brief introduction of occluder implantation for congenital heart disease
- Occluders are currently used to treat ventricular septal defect (VSD), atrial septal defect (ASD), and arterial duct occlusion (PDA). Traditional methods include surgical and medical intervention. Both methods are effective in treating congenital heart disease.
- Traditional surgery requires a midline or lateral thoracotomy, and requires extracorporeal circulation. The incision is long (15-20cm), the trauma is large, the operation time is long, and the fastest time is 2-3 hours. The pain is severe and the recovery is slow. , Long hospital stay, obvious skin scars, affecting aesthetics.
- The basic structure of the arterial duct occluder is a mushroom-like structure made of super-elastic nickel-titanium alloy, which is enclosed by a polymer biofilm. The mesh structure is filled with polyester polyester or Teflon ).
- Internal medicine intervention is mainly through an 8-10 mm incision made through a small catheter through the root of the thigh. The right groin artery or vein will be used to accurately place the occluder into the heart or blood vessel defect or abnormal channel. , Block it, and the operation is over. This method of interventional treatment of congenital heart disease is that there is no surgical incision, which does not affect the physical and mental development of the child. In a sense, it is a cosmetic surgery. The whole operation takes about 1 hour. On the second day after the operation, the patient could walk down and be discharged after one day of observation. The treatment effect is good. One month after the occluder is implanted in the heart, the human endothelial cells have covered its surface. Three months later, the endothelial cells completely embed the occluder, and the occluder will not fall off.
Occluder Further Reading
- 1. Mu Ruibin, Qin Yongwen. Membrane ventricular septal defect occluder development and clinical application progress, Journal of Interventional Radiology, 2004,13 (2): 181-184
- 2. Wu Weifeng, Zeng Xiaochun. Understanding of thrombus formation in room occluder after transcatheter occlusion, recent advances in contemporary cardiology, 2008, 366-370
- 3. Xu Liang, Xu Zhongying. Complications of interventional therapy for congenital atrial septal defect and its management, Chinese Journal of Interventional Imaging and Therapy, 5 (6): 480-484
- 4. Zhang Min, Gu Xiang, Xu Xiangdong, Wang Bing. Application of Color Doppler Ultrasound during Follow-up of Congenital Heart Occlusion Device, Chinese Tissue Engineering Research and Clinical Rehabilitation, 15 (16): 3013-3016
- 5. Jiang Shiliang. Severe late complications of interventional treatment of congenital heart disease, Chinese Journal of Interventional Cardiology, 2011,19 (1): 1-4